What Has Been The Evolution of the Stem Cell Manufacturing Market in Recent Years?
The stem cell manufacturing market has seen considerable growth due to a variety of factors.
• There has been significant growth in the stem cell manufacturing market in the past few years. The market size will increase from $17.5 billion in 2024 to $19.22 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion during the historical period can be linked to advancements in biotechnology, the establishment of research, development initiatives, clinical trials, therapeutic applications, setting up regulatory framework, and infrastructural investment.
How Will the Stem Cell Manufacturing Market in the Coming Years?
The Stem Cell Manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of stem cell manufacturing is predicted to witness substantial expansion in the upcoming years. The market is expected to soar to $30.27 billion by 2029, with a compound annual growth rate (CAGR) of 12.0%.
The anticipated expansion during this period can be accredited to a rise in funding and investment, expanding therapeutic applications, the introduction of cell-based therapies, an increase in clinical trials and approvals, as well as personalized and patient-specific therapies. Key trends forecasted for this period include emphasis on 3D bioprinting, growth in induced pluripotent stem cells (ipscs), implementation of automation and robotics, standardization and scalability, and advancements in bioreactor technology.
Which Factors Are Boosting Growth In The Stem Cell Manufacturing Market?
The anticipated increase in the elderly demographic is predicted to drive the stem cell manufacturing market's growth. The term 'geriatric population' generally refers to individuals who are 65 years or older. Owing to weakened immunity and advanced age, this population often suffers from a variety of diseases. The possibility of chronic diseases rises with age, and stem cell manufacturing could offer a solution to combat these illnesses. To illustrate, the Population Reference Bureau, a non-profit association based in Kenya, predicted in January 2024 that the demographic of Americans 65 and older would rise from 58 million in 2022 to 82 million by 2050, indicating a growth of 47%. The representation of this age bracket in the total population is also set to grow from 17% to 23% within the same timeframe. Therefore, the escalating elder demographic substantially contributes to the expansion of the stem cell manufacturing market.
What Key Areas Define The Segmentation Of The Global Stem Cell Manufacturing Market?
The stem cell manufacturing market covered in this report is segmented –
1) By Product: Consumables, Instruments, Stem Cell Lines
2) By Application: Research Applications, Clinical Application, Cell And Tissue Banking Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Academic Institutes, Research Laboratories And Contract Research Organizations, Hospitals And Surgical Centers, Cell And Tissue Banks, Other End Users
Subsegments:
1) By Consumables: Media And Reagents, Cell Culture Vessels, Assay Kits
2) By Instruments: Bioreactors, Cell Counters, Flow Cytometers
3) By Stem Cell Lines: Embryonic Stem Cell Lines, Adult Stem Cell Lines, Induced Pluripotent Stem Cell Lines (iPSCs)
Pre-Book The Stem Cell Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Stem Cell Manufacturing Market?
The advancement in technology is a significant trend noticed in the stem cell manufacturing industry. All players in this market are keen on utilizing technologically advanced tools and methods to stay competitive. As an example, Bluebird Bio Inc., a biotechnology company based in the US, gained approval from the U.S. Food and Drug Administration (FDA) for their revolutionary product ZYNTEGLO in August 2022. This one-time gene therapy is now approved for treating patients suffering from beta-thalassemia who require regular transfusion of red blood cells. An important aspect of this therapy is its ex-vivo technique, in which a modified beta-globin gene is fused into the patient’s own hematopoietic stem cells. This technique allows patients to generate normal hemoglobin levels. This groundbreaking treatment aims to lessen the dependency on transfusions, considerably lightening the load of treatment for beta-thalassemia patients. The sanctioning of ZYNTEGLO is a significant marker in gene therapy, offering potential cures and improving the life quality of those afflicted.
Who Are the Key Players In The Stem Cell Manufacturing Market?
Major companies operating in the stem cell manufacturing market include:
• Thermo Fisher Scientific Inc.
• Merck Millipore
• Stemcell Technologies
• Fujifilm Holdings Corporation
• Takara Bio Group
• Lonza Group AG
• Sartorius AG
• Bio-Rad Laboratories
• Becton Dickinson and Company
• Bio-Techne Corporation
• Miltenyi Biotec
• Terumo BCT Inc.
• Corning Inc.
• Eppendorf AG
• ViaCyte Inc.
• Merck KGaA
• Danaher Corporation
• Vericel Corporation
• American Cryostem Corporation
• Cellgenix GMBH
• Aspen Neuroscience Inc.
• Magenta Therapeutics Inc
• Pluristem Therapeutics Inc.
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• 3D Biomatrix Inc.
• Worthington Biochemical Corporation
• Bico Group
What Is The Most Dominant Region In The Stem Cell Manufacturing Market?
North America was the largest region in the stem cell manufacturing market in 2024. Europe was the second-largest region in the stem cell manufacturing market. The regions covered in the stem cell manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
